Back to Resource Center

Toward a Roadmap for Biomedical HIV Prevention Investment Standards:  Strategic Insights from Key Industry Stakeholders

Toward a Roadmap for Biomedical HIV Prevention Investment Standards: Strategic Insights from Key Industry Stakeholders

The United States Agency for International Development (USAID) is a major funder of biomedical HIV prevention product development. In response to USAID’s desire for standards to help guide decisions for prioritizing investments and integrating user perspectives at various stages of product development, the Initiative for MPTs (IMPT) provided technical assistance to USAID’s Office of HIV/AIDS (OHA) to develop a Biomedical HIV Prevention Product Investment Framework. The purpose of this framework is to provide high-level guidance for USAID on biomedical HIV prevention investment decisions that integrate user perspectives at various stages of product development, namely from the pre-clinical/discovery to regulatory phases. Critical to the development of this framework were consultations with experts representing global pharmaceutical organizations, smaller biotechnology companies, non-profit product developers, academia, and supporting agencies. 

Read the report

September 2019

Click for full info +

Full Info:


Resource Type:

Technical Brief

Citation:

The United States Agency for International Development (USAID) is a major funder of biomedical HIV prevention product development. In response to USAID’s desire for standards to help guide decisions for prioritizing investments and integrating user perspectives at various stages of product development, the Initiative for MPTs (IMPT) provided technical assistance to USAID’s Office of HIV/AIDS (OHA) to develop a Biomedical HIV Prevention Product Investment Framework.

Authors:

(IMPT) Initiative for Multipurpose Prevention Technologies

Health Risks(s):

  • HIV

Product type(s):

  • HIVinhibitor
  • HIVtests
  • HIVtreatment

Topic(s):

  • Development

Back to Resource Center